Hologic manufactures proprietary products for the healthcare needs of women... Show more
The Stochastic Oscillator for HOLX moved into oversold territory on August 27, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HOLX advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 226 cases where HOLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on August 25, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HOLX as a result. In of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HOLX turned negative on August 18, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HOLX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HOLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.060) is normal, around the industry mean (10.917). P/E Ratio (27.647) is within average values for comparable stocks, (58.712). Projected Growth (PEG Ratio) (1.469) is also within normal values, averaging (1.855). HOLX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (3.797) is also within normal values, averaging (38.490).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HOLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
a manufacturer of diagnostics products, medical imaging systems and surgical products
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
NUSC | 43.37 | 0.28 | +0.65% |
Nuveen ESG Small-Cap ETF | |||
JPMO | 16.85 | 0.01 | +0.06% |
YieldMax JPM Option Income Strategy ETF | |||
HFSP | 17.76 | N/A | N/A |
TradersAI Large Cap Equity & Cash ETF | |||
YBTC | 45.96 | -0.02 | -0.04% |
Roundhill Bitcoin Covered Cll Strat ETF | |||
BBBL | 48.44 | -0.08 | -0.15% |
BondBloxx BBB Rated 10+ Yr Corp Bd ETF |
A.I.dvisor indicates that over the last year, HOLX has been loosely correlated with ZBH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HOLX jumps, then ZBH could also see price increases.
Ticker / NAME | Correlation To HOLX | 1D Price Change % | ||
---|---|---|---|---|
HOLX | 100% | +0.15% | ||
ZBH - HOLX | 44% Loosely correlated | -0.70% | ||
RVTY - HOLX | 41% Loosely correlated | -2.89% | ||
BDX - HOLX | 41% Loosely correlated | +0.69% | ||
WAT - HOLX | 39% Loosely correlated | -0.51% | ||
QGEN - HOLX | 39% Loosely correlated | -1.78% | ||
More |
Ticker / NAME | Correlation To HOLX | 1D Price Change % |
---|---|---|
HOLX | 100% | +0.15% |
Pharmaceuticals category (391 stocks) | 21% Poorly correlated | +0.12% |
Pharmaceuticals: Other category (105 stocks) | 17% Poorly correlated | -0.29% |